CVE-2023-30995

CVE-2023-30995 is a high-severity vulnerability in Ibm Aspera Faspex with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-863.

Key facts

Description

IBM Aspera Faspex 4.0 through 4.4.2 and 5.0 through 5.0.5 could allow a malicious actor to bypass IP whitelist restrictions using a specially crafted HTTP request. IBM X-Force ID: 254268.

Frequently asked questions

What is CVE-2023-30995?
IBM Aspera Faspex 4.0 through 4.4.2 and 5.0 through 5.0.5 could allow a malicious actor to bypass IP whitelist restrictions using a specially crafted HTTP request. IBM X-Force ID: 254268.
How severe is CVE-2023-30995?
CVE-2023-30995 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity high, and availability none.
Is CVE-2023-30995 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (51st percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-30995?
CVE-2023-30995 affects Ibm Aspera Faspex. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-30995?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-30995 published?
CVE-2023-30995 was published on 2023-09-08 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Ibm Aspera Faspex

All CVEs affecting Ibm Aspera Faspex →

Other CWE-863 (Incorrect Authorization) vulnerabilities

Browse all CWE-863 (Incorrect Authorization) vulnerabilities →